Noerr B
Neonatal Netw. 1996 Sep;15(6):23-31.
Increasing numbers of neonates are receiving extracorporeal membrane oxygenation (ECMO). ECMO is an invasive, lifesaving technique used to treat respiratory failure when other technologies have failed. The pharmacokinetics of various drugs administered during ECMO are unclear. Drug clearance is altered during ECMO. Evidence exists for binding of multiple drugs to the ECMO circuit tubing. Also, the administration route of medications to neonates on ECMO varies, potentially impacting drug disposition. Questions exist regarding the effect technical components of ECMO might have on drug pharmacokinetics. Because little clinical information is available, nurses must have a heightened awareness of drug effects and the potential for untoward events while administering medications to neonates receiving ECMO This article reviews what is currently known regarding ECMO and pharmacotherapy.
越来越多的新生儿正在接受体外膜肺氧合(ECMO)治疗。ECMO是一种侵入性的救生技术,用于在其他技术失效时治疗呼吸衰竭。在ECMO治疗期间给予的各种药物的药代动力学尚不清楚。在ECMO期间药物清除会发生改变。有证据表明多种药物会与ECMO回路管道结合。此外,接受ECMO治疗的新生儿的药物给药途径各不相同,这可能会影响药物处置。关于ECMO的技术组件可能对药物药代动力学产生的影响存在疑问。由于几乎没有临床信息可用,护士在给接受ECMO治疗的新生儿用药时必须提高对药物作用和不良事件可能性的认识。本文综述了目前关于ECMO和药物治疗的已知情况。